Anti-platelet therapy after percutaneous transluminal coronary angioplasty in family medicine practice

Katarzyna R. Kotwa; Hanna Bachórzewska-Gajewska; Sławomir Dobrzycki

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Abstracting and indexing Contact Instructions for authors

1/2008
vol. 3

Send email

Copy url:

abstract:

Anti-platelet therapy after percutaneous transluminal coronary angioplasty in family medicine practice

Katarzyna R. Kotwa

,

Hanna Bachórzewska-Gajewska

,

Sławomir Dobrzycki

Przegląd Kardiodiabetologiczny 2008; 3, 1: 38–43

Online publish date: 2008/04/09

View full text Get citation

Atherosclerosis is a generalized disease with myocardial infarction, stroke and transient ischaemic attack as its most dangerous manifestations. Anti-platelet drugs play a basic part in the treatment of coronary artery disease (CAD). In particular, anti-platelet therapy is important in patients who have undergone percutaneous transluminal coronary angioplasty (PTCA). The family doctor who takes care of such patients sometimes has doubts concerning the length of their management and side effects of the anti-platelet therapy. This article is a review of current guidelines on the management of such cases and contains some practical clues concerning anti-platelet drugs.

keywords:

Anti-platelet therapy after percutaneous transluminal coronary angioplasty in family medicine practice

Katarzyna R. Kotwa , Hanna Bachórzewska-Gajewska , Sławomir Dobrzycki

anti-platelet drugs, coronary artery disease, percutaneous transluminal coronary angioplasty, family medicine practice

Katarzyna R. Kotwa

,

Hanna Bachórzewska-Gajewska

,

Sławomir Dobrzycki